Evaluation of the safety and efficacy of ABO non-identical apheresis platelets with reduced plasma transfusion
10.13303/j.cjbt.issn.1004-549x.2025.07.007
- VernacularTitle:ABO非同型少浆单采血小板输注的安全性及有效性评价
- Author:
Ronghua DIAO
1
;
Qianying RUAN
1
;
Lu BAI
2
;
Hong ZHANG
1
;
Zerong WANG
1
;
Lei FU
1
;
Shichun WANG
1
Author Information
1. Department of Blood Transfusion, First Affiliated Hospital of Army Medical University, Chongqing 400038, China; Chongqing Blood Center of the Chinese People's Liberation Army, Chongqing 400038, China
2. Department of Clinical Laboratory, First Affiliated Hospital of Army Medical University, Chongqing 400038, China
- Publication Type:Journal Article
- Keywords:
ABO blood group;
non-identical platelets;
non-identical platelets with reduced plasma;
platelet transfusion;
transfusion efficacy
- From:
Chinese Journal of Blood Transfusion
2025;38(7):909-914
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the safety and efficacy of ABO non-identical platelets with reduced plasma (ABO-NPRP) transfusion in patients with hematological diseases. Methods: A retrospective analysis was conducted on 52 therapeutic doses of apheresis platelets with reduced plasma prepared at Chongqing Blood Center of the Chinese People's Liberation Army. The transfusion efficacy (24 h CCI) and the transfusion adverse reactions of these apheresis platelets were also observed in 35 patients with hematological diseases in First Affiliated Hospital of Army Medical University. Comparisons were made with a control group consisting of patients who received only identical apheresis platelets during the same period. Meanwhile, the effect of ABO-NPRP on the subsequent platelet transfusion efficacy was observed. Results: There was no statistically significant difference in PDW, MPV, and PLCR before and after the preparation of apheresis platelets with reduced plasma (P>0.05), while the difference in platelet count was statistically significant [(2.86±0.34)×10
per therapeutic dose vs (2.46±0.28)×10
per therapeutic dose, P<0.001]; there was no statistically significant difference in the 24 h CCI transfusion efficacy between conventional identical apheresis platelets and ABO-NPRP, with transfusion efficacy rates of 76.60% and 78.85%, respectively (P>0.05); there was no statistically significant difference in platelet transfusion efficacy between the group with ABO-NPRP and the group without ABO-NPRP (completely identical transfusion group), with transfusion efficacy rates of 77.78% and 75.25%, respectively (P>0.05). Conclusion: ABO-NPRP transfusion is safe, effective, demonstrating comparable efficacy to conventional identical transfusion. It can serve as an important complementary strategy to optimize the utilization of blood resources.
